GLP-1s Are Being Linked to Fewer Serious Infections, Including TB
Recent studies suggest that GLP-1 medications like Ozempic and Mounjaro may provide health benefits beyond weight loss and diabetes management, including a reduced risk of serious infections like tuberculosis. Researchers observed that patients using these drugs showed lower infection rates compared to those on other diabetes treatments.
Why it matters
If confirmed, these findings could expand the therapeutic use of blockbuster GLP-1 drugs, potentially improving health outcomes for vulnerable populations beyond metabolic health.
The positive reputation of GLP-1 medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) continues to get bolstered. These drugs might even help keep some infectious diseases at bay.
Two studies in recent weeks have found a link between GLP-1 use and a reduced risk of diseases like tuberculosis or infections serious enough to send people to the hospital. Though more research is needed to confirm this connection, GLP-1 drugs could very well offer a buffer against certain infections, particularly among more vulnerable groups like people with type 2 diabetes.
“These findings suggest that beyond their established metabolic benefits, GLP-1RAs may confer additional advantages in lowering infection risk,” said the authors of one recent study, published late last month in the journal Nature Communications.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in